Navigation Links
Art Pappas Elected to NVCA Board of Directors
Date:5/15/2013

RESEARCH TRIANGLE PARK, N.C., May 15, 2013 /PRNewswire/ -- The National Venture Capital Association (NVCA) today announced the election of Arthur M. Pappas , managing partner of Pappas Ventures, to its board of directors. He will serve a four-year term. The appointment was made official at the association's annual meeting – VentureScape 2013 – in San Francisco.

Mr. Pappas has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. He founded Pappas Ventures in 1994, and works with a team that has invested in numerous life science companies that have created novel innovative products addressing unmet medical needs. Prior to forming Pappas Ventures, he held senior level leadership positions at several multinational pharmaceutical companies, for which he led operations and was responsible for the development, licensing and launch of a number of global products.

The NVCA serves as the venture capital community's trade association, representing more than 400 members by advocating for policies that encourage innovation and reward long term investment.

"It is an honor and a pleasure to join the NVCA Board of Directors, especially during such a critical time for the venture capital industry," said Mr. Pappas. "I look forward to working with the organization and the board in developing policies that can further foster innovation and facilitate the creation of good jobs throughout the U.S. economy."

The NVCA also appointed Josh Green , general partner of Mohr Davidow Ventures to serve as the 2013-2014 Chairman of the Board of Directors, effective immediately. Mr. Pappas joins the board along with five other newly-elected directors; Scott Kupor , Andreessen Horowitz; Sue Siegel , GE healthymagination; John Backus , New Atlantic Ventures; Mark Leschly , Rho Capital Partners; and Jim Healy , Sofinnova Ventures.

About Pappas Ventures

Founded in 1994, Pappas Ventures invests exclusively in the life sciences sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures. Pappas Ventures has more than $350 million in capital under management, and has guided the launch and/or development of more than 50 life sciences companies, including Arena Pharmaceuticals (Nasdaq: ARNA), Plexxikon (acquired by Daiichi Sankyo), Cerexa (acquired by Forest Laboratories), Peninsula Pharmaceuticals (acquired by Johnson & Johnson), NuVasive (Nasdaq: NUVA), TESARO (Nasdaq: TSRO), and Chimerix (Nasdaq: CMRX). For more information about Pappas Ventures please visit www.pappasventures.com.

CONTACT:
Ford S. Worthy
fworthy@pappasventures.com
919-998-3330

 


'/>"/>
SOURCE Pappas Ventures
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. SoundConnect Recently Selected by iCIMS, Inc.
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. ExakTime’s GeoTrakker Selected for 2013 Most Innovative Product Award Program
4. Greenphires ClinCard Technology Platform selected by Bavarian Nordic for Major Vaccine Trial
5. OPX Biotechnologies Selected as Innovation Pioneer at IHS CERAWeek
6. American Physical Society elected physicist Markus Aspelmeyer as a Fellow
7. Topricin Selected for Bruce Springsteen MusiCares’ Tribute Gala
8. Topricin Pain Relief and Healing Cream Selected by Healthy Holistic Living as one of the Top 100 Green Products of 2012
9. INRS: Professor Federico Rosei elected AAAS Fellow in recognition of his meritorious efforts to advance science
10. Cantrell Selected to Lead Kansas Bioscience Authority
11. Companies Selected to Present at AdvaMed 2012 Announced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , ... February 24, 2017 , ... Delpor, Inc. (Delpor), ... grant from the National Institute of Mental Health (NIMH) for the further advancement of ... PROZOR technology and is expected to deliver therapeutic levels of olanzapine for ...
(Date:2/24/2017)... FRANCISCO , Feb. 24, 2017 Symic ... is developing a new category of therapeutics, announced today ... of SB-030 in peripheral artery disease. The trial will ... administered single-use therapeutic, in the reduction of restenosis following ... this critical development milestone for SB-030," said Nathan ...
(Date:2/24/2017)... Feb. 23, 2017 China Biologic Products, Inc. (NASDAQ: ... plasma-based biopharmaceutical company in China, today announced its financial results ... Fourth Quarter 2016 Financial Highlights ... by 21.7% in RMB terms, or increased by 13.6% in ... same quarter of 2015. Gross profit increased ...
(Date:2/23/2017)... Feb. 23, 2017 ... except per share data, unaudited)Three Months Ended December 31,Twelve ... Revenue $       ... 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  756025%297303(2)%Vimizim ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/2/2017)... TOKYO , Feb. 1, 2017  Central ... innovative and meaningful advances worldwide, The Japan Prize ... Japan Prize, who have pushed the envelope in ... Information and Communication. Three scientists are being recognized ... outstanding achievements that not only contribute to the ...
Breaking Biology News(10 mins):